Akero Therapeutics, Inc. (AKRO)
After hours:
| Previous close | 18.82 |
| Open | 19.47 |
| Bid | 19.13 x 400 |
| Ask | 19.21 x 400 |
| Day's range | 18.96 - 19.92 |
| 52-week range | 11.25 - 58.38 |
| Volume | |
| Avg. volume | 1,023,438 |
| Market cap | 1.327B |
| Beta (5Y monthly) | -0.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.24 |
| Earnings date | 09 Aug 2024 - 13 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 46.50 |
GlobeNewswireAkero Therapeutics to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 4:00 p.m. E.T. in New York, NY. A live webcast of the Company presentation will be available through the investor relations section
GuruFocus.comAkero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...
Comprehensive Analysis of Financial Performance and Strategic Progress
- GlobeNewswire
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
-- Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 -- -- Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to enroll; SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4) on track to be initiated in second quarter of 2024 -- SOUTH SAN FRANCISCO, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Akero Ther
